AzTrials
AzTrials

MenopauseNCT01899612

Vaginal Inflammation Markers in Postmenopausal Women With and Without Symptoms of Vaginal Inflammation

An observational study of Menopause and Vaginal Atrophy, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Many postmenopausal women suffer from vaginal symptoms such as dryness, itching, and painful intercourse. The underlying pathology is unknown. Since symptoms are comparable to those found in infectious vaginitis during the reproductive life stage, the investigators hypothesize that the vaginal milieu in symptomatic… Read more about this study

Who is it for?
Ages 40 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Menopause, Vaginal Atrophy
How many people
16 participants
Where
1 siteSwitzerland
Study dates
Aug 2010to Dec 2012
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: All subjects will be recruited at the menopause center, Inselspital Berne.

Who may be able to join

  • Age of 40 years or older
  • At least 1 year history of amenorrhea
  • Normal Pap smear within the past year
  • Willingness to abstain from sexual intercourse and use of over-the-counter vaginal products for 7 days before the collection of vaginal samples
  • Written informed consent.

Who cannot join

  • Administration of any form of oral hormone replacement therapy within 2 months, transdermal or vaginal hormone replacement therapy for 1 months prior to entry into the study
  • Active vulvovaginal candidiasis, trichomonas vaginitis or bacterial vaginitis based on vaginal wet prep, pH, whiff test and KOH preparation;
  • Untreated cervical, vaginal or vulvar intraepithelial neoplasia;
  • Active sexually transmitted diseases including herpes simplex viral infection, gonorrhea and Chlamydia
  • Pessary-users
  • Active treatment with tamoxifen, raloxifene or other forms of selective estrogen receptor modulators (SERMs);
Show all 10Show fewer
  • Undiagnosed vaginal bleeding
  • Hysterectomy
  • Past or current history breast cancer, endometrial cancer or endometrial hyperplasia, hypertriglyceridemia or venous thromboembolism
  • Immunocompromised patient including those with human immunodeficiency viral infection, chronic glucocorticoid use or active treatment with immunosuppressive agents

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Menopause Clinic, Women's Hospital, Inselspital Bern

    Bern, 3010

Other trials in Switzerland

About this study

Official title: Vaginal Cytokines in Postmenopausal Women With Symptoms of Vulvovaginal Irritation

Many postmenopausal women suffer from vaginal symptoms such as dryness, itching, and painful intercourse. The underlying pathology is unknown. Since symptoms are comparable to those found in infectious vaginitis during the reproductive life stage, the investigators hypothesize that the vaginal milieu in symptomatic postmenopausal women is comparable to inflammation in vaginitis. The investigators therefore study vaginal cytokines in symptomatic and asymptomatic postmenopausal women.

Read the detailed description

Background

Vulvovaginal irritation is a frequent complaint among postmenopausal women who are not on hormone therapy. Common symptoms include pruritus. Patients describe the irritation to be similar to that of vulvovaginal candidiasis during their reproductive years. Clinical improvement is seen with estrogen therapy. Most clinicians attribute the symptoms to vaginal dryness secondary to estrogen deficiency. However, the underlying pathophysiology of this clinical entity is not well defined. Since cytokines have been shown to play a significant role in the pathogenesis of infectious vaginitis, and there is evidence to suggest that estrogen influences cytokine production, we postulate that estrogen deficiency causes a disturbance in the vaginal cytokine environment similar to that of infectious vulvovaginitis.

Studies that investigate the pathogenesis of bacterial vaginosis, vulvovaginal candidiasis, and vestibulitis have identified changes in the level of antibodies and cytokines in the vagina during these processes. Donders and co-workers performed a study looking at the correlation between disturbance of the lactobacillary flora, vaginal pH, interleukin 1beta (IL-1b), and interleukin 8 (IL-8). Menopausal women were excluded from this study. Vaginal pH, IL-8, and IL-1β concentrations increased linearly with decreasing lactobacilli by 4 to 10 fold. IL-1β concentration was most closely related to decreasing lactobacilli, and IL-8 concentration was most closely related to positive culture results. Regúlez, Garcia Fernández, and co-worker performed a study to correlate the symptoms of vulvovaginal candidiasis with vaginal IgE levels. Patients who have clinically overt vulvovaginal candidiasis with classical symptomatology regardless of whether yeast or mycelia is identified in fresh smear or culture had higher IgE levels in their vagina than asymptomatic carriers or uninfected controls. This variation of host response has been proposed as one of the mechanism why only some women with vulvovaginal candidiasis experience symptoms. This concept of an imbalance between TH1 to TH2 cell reactivity with preference to the latter was further suggested by Puccetti, Romani and Bistoni. In contrary to the findings by Regúlez, Garcia Fernández and co-workers, Fidel, Ginsburg, and co-workers studied the vaginal-associated immunity in women with recurrent vulvovaginal candidiasis and found that Th-1 type response is increased. This area is certainly controversial and requires further investigations. Since IL-6 has been suggested as one of the cytokines involved in Th-2 or immediate-type hypersensitivity response, it will be of interest to study whether its level is increased for patients with symptomatology. Foster and Hasday compared the levels of IL-1b, and tumor necrosis factor-alpha (TNF-a) in perineal biopsy between women with vulvar vestibulitis and pain-free subjects, and found an increase in both cytokines in the former cases.

Estrogen has been shown to influence cytokine activity in the reproductive tract. García-Velasco and Arici published a review article on chemokines and human reproduction. In the article, the clinical relevance of chemokines in normal human reproductive events such as ovulation, menstruation, and implantation were summarized. There was however little information on their relevance in vaginal physiology. This is consistent with the little information on the topic of vaginal physiology in the literature. A study by Franklin, and Kutteh on the variation of immunoglobulins, and cytokines in cervical mucus in twelve women on oral contraceptives (OCs), and fifteen naturally cycling women showed a definite influence of exogenous and endogenous hormones on their levels. Cervical IgA, and IL-1b levels in women taking Ortho Novum 777® paralleled the increasing dosage of oral norethindrone, and the levels decreased after discontinuation of the oral contraceptive. Cervical IL-1b, and IL-10 both peaked just before ovulation in natural cycles. Cervical mucus IL-1b levels were found to correlate directly to changes in estrogen level during a natural cycle. Vaginal cytokine levels were not investigated in the study. Al-Harth, and co-workers measured cervicovaginal IL-1b, IL-4, IL-6, IL-8, IL-10, interferon-gamma (INF-gamma), transforming growth factor-beta (TGF-b), tumor necrosis factor-alpha (TNF-a), macrophage inflammatory protein-1alpha (MIP-1a) and TNG receptor II (TNFR II) during the follicular, and luteal phases of ovulatory cycle of six premenopausal women. Cervicovaginal IL-1b, and IL-6 were found to vary in level throughout the ovulatory cycle. Both IL-1b, and IL-6 were 5-fold higher in the follicular phase than in the luteal phase. Other cervicovaginal cytokines levels were not altered between the two phases. Plasma IL-8 level was higher in the follicular than luteal phase. The investigators' hypothesis is that postmenopausal estrogen deficiency causes changes in cytokine levels in the vagina similar to that found with vaginal candidiasis and bacterial vaginosis. A common cytokine etiology will account for the similarity of the symptomatology of infectious vaginitis and postmenopausal vaginal irritation.

Unpublished preliminary data from a study done on premenopausal women by Ballagh in the co-operating Howard and Georgeanna Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia, USA, has shown that the mean levels of vaginal IL-1b and IL-8, as measured by ELISA, are higher in the luteal phase than the follicular phase in naturally cycling women. The median level of IL-1b is higher in the luteal phase than follicular phase but that of IL-8 is higher in the follicular phase than luteal phase. These results show that vaginal interleukin environment varies throughout the menstrual cycle to another. Women on oral contraceptive pills have increased mean levels of both vaginal IL-1b, and IL-8 compared to naturally cycling women. These data, though preliminary, support the theory that steroid hormone may play a role in the regulation of vaginal cytokine levels.

Objective

The principal goal of this pilot study is to determine the correlation between postmenopausal vulvovaginal irritative symptoms with vaginal interleukin levels. Cytokines to be evaluated in vaginal lavage will include IL-1β, IL-6, IL-8 and TNF-α. Plasma interleukin levels will be assessed concurrently, and compared to the vaginal levels to ensure that the vaginal levels obtained are not a result of contamination by plasma transudate. This study is thought to be the basis for a future randomised controlled trial involving the treatment of symptomatic menopausal women for investigation whether the resolution of the symptoms with e.g. estrogen and DHEA therapy is associated with a decrease in the interleukin levels.

Methods

Screening Investigations (visit 1):

History and physical examination Vaginal pH, KOH prep, whiff test, and wet prep for Trichomonas vaginalis Cervical sample for Neisseria gonorrhea \& Chlamydia trachomatis assay

Enrollment Investigations (visit 2):

  1. Vaginal pH
  2. Vaginal smear for Nugent score and maturation index
  3. Vaginal wet prep for Trichomonas vaginalis
  4. Vaginal KOH prep and whiff test
  5. Speculum examination and vaginal lavage
  6. Leukocyte counts in vaginal samples
  7. ELISA for serum IL-1b, IL-6, IL-8, TNF-a, IgE and estradiol
  8. ELISA for IL-1b, IL-6, IL-8 TNF-a and IgE in vaginal lavage samples
Keywords
menopause, vaginal atrophy, cytokine, IL-1beta, IL-6, IL-8, TNF-alpha

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01899612
Study groupRoleWhat they receive
Symptomatic postmenopausal womenPostmenopausal women with vulvovaginal symptoms
Asymptomatic postmenopausal womenPostmenopausal women without vulvovaginal symptoms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference in total vaginal IL-1beta in postmenopausal patients symptomatic, and asymptomatic of vulvovaginal irritation.

    Measured: At enrolment (expected to be 2 weeks after screening)

Secondary outcomes (4)
  1. Difference in total vaginal IL-6 in postmenopausal patients symptomatic, and asymptomatic of vulvovaginal irritation.

    Measured: At enrolment (expected to be 2 weeks after screening)

  2. Difference in total vaginal IL-8 in postmenopausal patients symptomatic, and asymptomatic of vulvovaginal irritation.

    Measured: At enrolment (expected to be 2 weeks after screening)

  3. Difference in total vaginal TNF-alpha in postmenopausal patients symptomatic, and asymptomatic of vulvovaginal irritation.

    Measured: At enrolment (expected to be 2 weeks after screening)

  4. Difference in vaginal leukocyte counts in postmenopausal patients symptomatic, and asymptomatic of vulvovaginal irritation.

    Measured: At enrolment (expected to be 2 weeks after screening)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2013 (estimated)
  2. Study startAug 2010
  3. Primary completionDec 2012
  4. Study completionDec 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01899612
Sponsor's protocol ID
58/10
Status last verified
Jul 2013
First submitted
10 Jul 2013
Last updated
15 Jul 2013
Results posted
No
Data monitoring committee
No

Publications

  • Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause. 2000 Sep-Oct;7(5):310-7. doi: 10.1097/00042192-200007050-00005.

    PubMed 10993030
  • Al-Harthi L, Wright DJ, Anderson D, Cohen M, Matity Ahu D, Cohn J, Cu-Unvin S, Burns D, Reichelderfer P, Lewis S, Beckner S, Kovacs A, Landay A. The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res. 2000 Aug;20(8):719-24. doi: 10.1089/10799900050116426.

    PubMed 10954915
  • Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol. 1999 Mar;42(2):93-106. doi: 10.1016/s0165-0378(98)00086-2.

    PubMed 10221733
  • Kollmann Z, Bersinger N, von Wolff M, Thurman AR, Archer DF, Stute P. Vaginal cytokines do not correlate with postmenopausal vulvovaginal symptoms. Gynecol Endocrinol. 2015 Apr;31(4):317-21. doi: 10.3109/09513590.2014.995080. Epub 2015 Jan 5.

    PubMed 25559048

Questions about this trial

What is this clinical trial studying?

An observational study of Menopause and Vaginal Atrophy, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference in total vaginal IL-1beta in postmenopausal patients symptomatic, and asymptomatic of vulvovaginal irritation. (time frame: At enrolment (expected to be 2 weeks after screening)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01899612, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in